Related Experiment Video
Updated: Jul 27, 2026
08:45
Polygraphic Recording Procedure for Measuring Sleep in Mice
Published on: January 26, 2016
Emerging therapies in narcolepsy-cataplexy
Emmanuel Mignot1, Seiji Nishino
1Howard Hughes Medical Research Institute, Stanford University School of Medicine, Stanford, CA, USA. mignot@leland.stanford.edu
Sleep
|February 16, 2006
Summary
Narcolepsy treatments are evolving beyond symptom management. Emerging therapies aim to address the underlying hypocretin deficiency and explore novel compounds for improved patient outcomes.
Area of Science:
- Neurology
- Sleep Medicine
- Pharmacology
Background:
- Narcolepsy historically treated with stimulants and antidepressants.
- Current treatments like modafinil, venlafaxine, atomoxetine, and sodium oxybate offer symptomatic relief.
- These therapies do not address the core hypocretin neurotransmitter deficiency in narcolepsy.
Purpose of the Study:
- To review emerging therapies for narcolepsy.
- To discuss novel strategies targeting hypocretin deficiency.
- To explore new antidepressant, anticataplectic, wake-promoting, and hypnotic compounds.
Main Methods:
- Literature review of emerging narcolepsy treatments.
- Discussion of novel therapeutic strategies.
- Examination of immunomodulatory approaches.
Main Results:
- Emerging therapies include novel compounds and strategies targeting hypocretin deficiency.
- Newer agents offer improved tolerability and efficacy.
- Immunosuppression is being investigated for early-stage narcolepsy.
Conclusions:
- Emerging narcolepsy therapies focus on addressing hypocretin deficiency.
- Novel pharmacological agents and treatment strategies promise better patient outcomes.
- Future research directions include targeted therapies and immunomodulation.
Related Concept Videos
01:26Cholinergic Antagonists: Therapeutic Uses
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
01:24Sleep-Wake Cycles
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:07Narcolepsy
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...